Overview
PABA is taken for a disease that causes curved, painful erections (Peyronie disease), a rare autoimmune disorder that causes skinblisters (pemphigus), hardening of skin and connective tissue (scleroderma), and many other conditions. But there is no good scientific evidence to support these uses.
PABA is best known as a sunscreen that is applied to the skin.
How does it work ?
Uses & Effectiveness ?
Effective for
Possibly Effective for
- Peyronie disease. PABA is FDA-approved for use in this condition.
Possibly Ineffective for
- Hardening of skin and connective tissue (scleroderma). Although PABA is FDA-approved for scleroderma, there is only limited evidence that it is effective. Not all research has shown benefit.
Insufficient Evidence for
- Infection of the eye caused by herpes virus (herpes keratitis). Early research suggests that using a specific PABA eye solution (Actipol) as eye drops can treat this condition.
- Conditions involving long-term muscle inflammation (swelling) and weakness (inflammatory myopathies). PABA is approved by the FDA for this skin condition. But there is only limited evidence that it is effective.
- A rare autoimmune disorder that causes skin blisters (pemphigus). PABA is approved by the FDA for this skin condition. But there is only limited evidence that it is effective.
- A skin disorder that causes white patches to develop on the skin (vitiligo).
- Arthritis.
- Constipation.
- Headaches.
- Preventing hair loss.
- Darkening gray hair.
- Other conditions.
Side Effects
When applied to the skin: PABA is LIKELY SAFE for most people when applied directly to the skin. There haven't been any reports of serious harm. But there have been reports that PABA increases the risk for sunburn in some people, even though it usually works as a sunscreen.
When applied into the eye: PABA is POSSIBLY SAFE when a solution is used as an eye drop in the eyes.
Special Precautions and Warnings
When applied to the skin: PABA is LIKELY SAFE for most people when applied directly to the skin. There haven't been any reports of serious harm. But there have been reports that PABA increases the risk for sunburn in some people, even though it usually works as a sunscreen.
When applied into the eye: PABA is POSSIBLY SAFE when a solution is used as an eye drop in the eyes. Pregnancy and breast-feeding: PABA is LIKELY SAFE when applied to the skin during pregnancy or breast-feeding. There isn't enough reliable information to know if PABA is safe to take by mouth when pregnant or breast-feeding. Stay on the safe side and avoid use.
Children: When applied directly to the skin, PABA is LIKELY SAFE for children. PABA is POSSIBLY SAFE for children when taken by mouth in doses of 220 mg/kg daily or less. PABA is POSSIBLY UNSAFE when taken by mouth in higher doses.
Kidney disease: PABA might build up in the kidneys making kidney disease worse. Do not use it if you have kidney problems.
Interactions ?
Antibiotics (Sulfonamide antibiotics) interacts with PARA-AMINOBENZOIC ACID (PABA)
Para-aminobenzoic acid (PABA) can decrease the effectiveness of certain antibiotics called sulfonamides.
Some of these antibiotics include sulfamethoxazole (Gantanol), sulfasalazine (Azulfidine), sulfisoxazole (Gantrisin), and trimethoprim/sulfamethoxazole (Bactrim, Septra).Dapsone (Avlosulfon) interacts with PARA-AMINOBENZOIC ACID (PABA)
Dapsone (Avlosulfon) is used as an antibiotic. Para-aminobenzoic acid (PABA) might decrease the effectiveness of dapsone (Avlosulfon) for treating infections.
Major Interaction
Do not take this combination
Cortisone interacts with PARA-AMINOBENZOIC ACID (PABA)
The body breaks down cortisone to get rid of it. Para-aminobenzoic acid (PABA) might decrease how quickly the body breaks down cortisone. Taking PABA by mouth and getting a cortisone shot might increase the effects and side effects of cortisone.
Moderate Interaction
Be cautious with this combination
Dosing
ADULTS
BY MOUTH:
- For Peyronie disease: A specific PABA product (POTABA, Glenwood LLC.) 12 grams daily in four divided doses with meals for 8-24 months has been used.
- For sunburn: Sunscreens with 1% to 15% PABA have been used.
APPLIED TO THE SKIN:
- For sunburn: Sunscreens with 1% to 15% PABA have been used.
Rees K, Hartley L, Day C, et al. Selenium supplementation for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013;1:CD009671. View abstract.
Reid ME, Duffield-Lillico AJ, Garland L, et al. Selenium supplementation and lung cancer incidence: an update of the nutritional prevention of cancer trial. Cancer Epidemiol Biomarkers Prev 2002;11:1285-91.. View abstract.
Reid SM, Middleton P, Cossich MC, Crowther CA. Interventions for clinical and subclinical hypothyroidism in pregnancy. Cochrane Database Syst Rev 2010;(7):CD007752. View abstract.
Rivera JA, González-Cossío T, Flores M, et al. Multiple micronutrient supplementation increases the growth of Mexican infants. Am J Clin Nutr. 2001 Nov;74:657-63. View abstract.
Robinson MF, Thomson CD, Jenkinson CP, et al Long-term supplementation with selenate and selenomethionine: urinary excretion by New Zealand women. Br J Nutr 1997;77:551-63.. View abstract.
Schiavon R, Freeman GE, Guidi GC, et al. Selenium enhances prostacyclin production by cultured endothelial cells: possible explanation for increased bleeding times in volunteers taking selenium as a dietary supplement. Thromb Res 1984;34:389-96. View abstract.
Schrauzer GN, Sacher J. Selenium in the maintenance and therapy of HIV-infected patients. Chem Biol Interact 1994;91:199-205.. View abstract.
Schrauzer GN. Anticarcinogenic effects of selenium. Cell Mol Life Sci 2000;57:1864-73. View abstract.
Schrauzer GN. Nutritional selenium supplements: product types, quality, and safety. J Am Coll Nutr 2001;20:1-4. View abstract.
Schrauzer GN. Selenomethionine: a review of its nutritional significance, metabolism and toxicity. J Nutr 2000;130:1653-6. View abstract.
Schwingshackl L, Boeing H, Stelmach-Mardas M, et al. Dietary Supplements and Risk of Cause-Specific Death, Cardiovascular Disease, and Cancer: A Systematic Review and Meta-Analysis of Primary Prevention Trials. Adv Nutr. 2017;8(1):27-39. View abstract.
See KA, Lavercombe PS, Dillon J, Ginsberg R. Accidental death from acute selenium poisoning. Med J Aust 2006;185:388-9. View abstract.
Seidner DL, Lashner BA, Brzezinski A, et al. An oral supplement enriched with fish oil, soluble fiber, and antioxidants for corticosteroid sparing in ulcerative colitis: a randomized, controlled trial. Clin Gastroenterol Hepatol 2005;3:358-69. View abstract.
Shen CL, Song W, Pence BC. Interactions of selenium compounds with other antioxidants in DNA damage and apoptosis in human normal keratinocytes. Cancer Epidemiol Biomarkers Prev 2001;10:385-90. View abstract.
Sher L. Role of selenium depletion in the etiopathogenesis of depression in patient with alcoholism. Med Hypotheses 2002;59:330-3.. View abstract.
Shiobara Y, Yoshida T, Suzuki KT. Effects of dietary selenium species on Se concentrations in hair, blood, and urine. Toxicol Appl Pharmacol 1998;152:309-14. View abstract.
Sieja K, Talerczyk M. Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy. Gynecol Oncol 2004;93:320-7. View abstract.
Sirikonda NS, Patten WD, Phillips JR, Mullet CJ. Ketogenic diet: Rapid onset of selenium deficiency-induced cardiac decompensation. Pediatr Cardiol 2012;33(5):834-8. View abstract.
Smith DK, Feldman EB, Feldman DS. Trace element status in multiple sclerosis. Am J Clin Nutr 1989;50:136-40. View abstract.
Song M, Kumaran MN, Gounder M, et al. Phase I trial of selenium plus chemotherapy in gynecologic cancers. Gynecol Oncol. 2018 Sep;150(3):478-486. doi: 10.1016/j.ygyno.2018.07.001. Epub 2018 Jul 29. View abstract.
Sors TG, Ellis DR, Na GN, et al. Analysis of sulfur and selenium assimilation in Astragalus plants with varying capacities to accumulate selenium. Plant J 2005;42:785-97. View abstract.
Srivastava Y, Venkatakrishna-Bhatt H, Verma Y, et al. Antidiabetic and adaptogenic properties of Momordica charantia extract: An experimental and clinical evaluation. Phytother Res 1993;7:285-9.
Stein TP, Schluter MD, Leskiw MJ, Boden G. Attenuation of the protein wasting associated with bed rest by branched-chain amino acids. Nutrition 1999;15:656-60. View abstract.
Stewart MS, Spallholz JE, Neldner KH, Pence BC. Selenium compounds have disparate abilities to impose oxidative stress and induce apoptosis. Free Radic Biol Med 1999;26:42-8. View abstract.
Stranges S, Laclaustra M, Ji C, et al. Higher selenium status is associated with adverse blood lipid profile in British adults. J Nutr 2010;140:81-7. View abstract.
Stranges S, Marshall JR, Natarajan R, et al. Effects of long-term selenium supplementation on the incidence of type 2 diabetes. Ann Intern Med 2007;147:217-23. View abstract.
Sudfeld CR, Aboud S, Kupka R, et al. Effect of selenium supplementation on HIV-1 RNA detection in breast milk of Tanzanian women. Nutrition 2014;30(9):1081-4. View abstract.
Sutter ME, Thomas JD, Brown J, Morgan B. Selenium toxicity: a case of selenosis caused by a nutritional supplement. Ann Intern Med 2008;148:970-1. View abstract.
Taylor PR, Parnes HL, Lippman SM. Science peels the onion of selenium effects on prostate carcinogenesis. J Natl Cancer Inst 2004;96:645-7. View abstract.
Thompson PA, Ashbeck EL, Roe DJ, et al. Selenium Supplementation for Prevention of Colorectal Adenomas and Risk of Associated Type 2 Diabetes. J Natl Cancer Inst. 2016;108(12). View abstract.
Thomson CD, Robinson MF. Urinary and fecal excretions and absorption of a large supplement of selenium: superiority of selenate over selenite. Am J Clin Nutr 1986;44:659-63.. View abstract.
Tian X, Li N, Su R, Dai C, Zhang R. Selenium supplementation may decrease thyroid peroxidase antibody titer via reducing oxidative stress in euthyroid patients with autoimmune thyroiditis. Int J Endocrinol. 2020;2020:9210572. View abstract.
Toulis KA, Anastasilakis AD, Tzellos TG, et al. Selenium supplementation in the treatment of Hashimoto's thyroiditis: A systematic review and a meta-analysis. Thyroid 2010;20:1163-73. View abstract.
Trafikowska U, Zachara BA, Wiacek M, et al. Selenium supply and glutathione peroxidase activity in breastfed Polish infants. Acta Paediatr 1996;85:1143-5. View abstract.
Turker O, Kumanlioglu K, Karapolat I, Dogan I. Selenium treatment in autoimmune thyroiditis: 9-month follow-up with variable doses. J Endocrinol 2006;190:151-6. View abstract.
Ustundag Y, Boyacioglu S, Haberal A, et al. Plasma and gastric tissue selenium levels in patients with Helicobacter pylori infection. J Clin Gastroenterol 2001;32:405-8. View abstract.
Vaddadi KS, Soosai E, Vaddadi G. Low blood selenium concentrations in schizophrenic patients on clozapine. Br J Clin Pharmacol 2003;55:307-9. View abstract.
Van Dael P, Davidsson L, Munoz-Box R, et al. Selenium absorption and retention from a selenite- or selenate-fortified milk-based formula in men measured by a stable-isotope technique. Br J Nutr 2001;85:157-63.. View abstract.
Vanderpas JB, Contempre B, Duale NL, et al. Selenium deficiency mitigates hypothyroxinemia in iodine-deficient subjects. Am J Clin Nutr 1993;57:271S-5S. View abstract.
Varikasuvu SR, Prasad V S, Kothapalli J, Manne M. Brain Selenium in Alzheimer's Disease (BRAIN SEAD Study): a Systematic Review and Meta-Analysis. Biol Trace Elem Res. 2019;189(2):361-369. View abstract.
Venkateswaran V, Fleshner NE, Klotz LH. Synergistic effect of vitamin E and selenium in human prostate cancer cell lines. Prostate Cancer Prostatic Dis 2004;7:54-6. View abstract.
Vermeulen NP, Baldew GS, Los G, et al. Reduction of cisplatin nephrotoxicity by sodium selenite. Lack of interaction at the pharmacokinetic level of both compounds. Drug Metab Dispos 1993;21:30-6. View abstract.
Vernie LN, de Goeij JJ, Zegers C, et al. Cisplatin-induced changes of selenium levels and glutathione peroxidase activities in blood of testis tumor patients. Cancer Lett 1988;40:83-91. View abstract.
Verrotti A, Basciani F, Trotta D, et al. Serum copper, zinc, selenium, glutathione peroxidase and superoxide dismutase levels in epileptic children before and after 1 year of sodium valproate and carbamazepine therapy. Epilepsy Res 2002;48:71-5. View abstract.
Vinceti M, Filippini T, Del Giovane C, et al. Selenium for preventing cancer. Cochrane Database Syst Rev. 2018;1:CD005195. View abstract.
Vinceti M, Filippini T, Rothman KJ. Selenium exposure and the risk of type 2 diabetes: a systematic review and meta-analysis. Eur J Epidemiol. 2018 Sep;33(9):789-810. Epub 2018 Jul 5. Review. View abstract.
Vinceti M, Rothman KJ, Bergomi KJ, et al. Excess melanoma incidence in a cohort exposed to high levels of environmental selenium. Cancer Epidemiol Biomarkers Prev 1998;7:853-6. View abstract.
Vostalova J, Vidlar A, Ulrichova J, et al. Use of selenium-silymarin mix reduces lower urinary tract symptoms and prostate specific antigen in men. Phytomedicine 2013;21:75-81. View abstract.
Wang GQ, Dawsey SM, Li JY, et al. Effects of vitamin/mineral supplementation on the prevalence of histological dysplasia and early cancer of the esophagus and stomach: results from the General Population Trial in Linxian, China. Cancer Epidemiol Biomarkers Prev 1994;3:161-6. View abstract.
Wang L, Wang J, Liu X, Liu Q, Zhang G, Liang L. Association between selenium intake and the risk of pancreatic cancer: a meta-analysis of observational studies. Biosci Rep. 2016;36(5). View abstract.
Wasowicz W, Gromadzinska J, Szram K, et al. Selenium, zinc, and copper concentrations in the blood and milk of lactating women. Biol Trace Elem Res 2001;79:221-33.. View abstract.
Watanabe C, Kim CY, Satoh H. Tissue-specific modification of selenium concentration by acute and chronic dexamethasone administration in mice. Br J Nutr 1997;78:501-9. View abstract.
Abarca, J., Odilla, Arrollo C., Blanch, S., and Arellano, G. [Melasma in pregnancy: reduction of its appearance with the use of a broad-spectrum photoprotective agent]. Med Cutan.Ibero.Lat.Am 1987;15(3):199-203. View abstract.
Akberova, S. I. [Actipol in treating stromal herpetic keratitis]. Vestn.Oftalmol. 2002;118(2):17-19. View abstract.
Akberova, S. I. [Para-aminobenzoic acid and prospects of its use in ophthalmology]. Vestn.Oftalmol. 2002;118(3):53-56. View abstract.
Akberova, S. I. and Musaev Galbinur, P. I. [The new interferon inducer Aktipol in the treatment of herpetic keratitis]. Vestn.Oftalmol. 2000;116(2):16-18. View abstract.
Akberova, S. I., Musaev Galbinur, P. I., Stroeva, O. G., Magomedov, N. M., Babaev, N. F., and Galbinur, A. P. [Comparative evaluation of the antioxidant activity of para-aminobenzoic acid and emoxipin in the cornea and crystalline lens (an experimental study)]. Vestn.Oftalmol. 2001;117(4):25-29. View abstract.
Ludwig G. Evaluation of conservative therapeutic approaches to Peyronie's disease (fibrotic induration of the penis). Urol Int 1991;47:236-9. View abstract.
Pathak MA. Sunscreens: Topical and systemic approaches for protection of human skin against harmful effects of solar radiation. J Am Acad Dermatol 1982;7:285-312. View abstract.
Sieve BF. The clinical effects of a new B Complex Factor, para-aminobenzoic acid, on pigmentation and fertility. Southern Medicine & Surgery 1942;135-9.
Wiesel LL, Barritt AS, Stumpe WM. The synergistic action of para-aminobenzoic acid and cortisone in the treatment of rheumatoid arthritis. Am J Med Sci 1951;243-8.
Worobec S, LaChine A. Dangers of orally administered para-aminobenzoic acid. JAMA 1984;251:2348.
Zarafonetis CJ, Dabich L, DeVol EB, et al. Potassium para-aminobenzoate and liver function test findings. J Am Acad Dermatol 1986;15:144-9. View abstract.
Zarafonetis CJ, Dabich L, Devol EB, et al. Retrospective studies in scleroderma: pulmonary findings and effect of potassium p-aminobenzoate on vital capacity. Respiration 1989;56:22-33. View abstract.
Zarafonetis CJ, Dabich L, Negri D, et al. Retrospective studies in scleroderma: effect of potassium para-aminobenzoate on survival. J Clin Epidemiol 1988;41:193-205. View abstract.
Zarafonetis CJ, Dabich L, Skovronski JJ, et al. Retrospective studies in scleroderma: skin response to potassium para-aminobenzoate therapy. Clin Exp Rheumatol 1988;6:261-8. View abstract.
Zarafonetis CJ, Horrax TM. Treatment of peyronie's disease with para-aminobenzoacidic potassium (POTOBA). J Urol 1959;81:770-2.
Zarafonetis CJ. Darkening of gray hair during para-amino-benzoic acid therapy. J Invest Dermatol 1950;399-401.
Select a condition to view a list of vitamins
You Might Also Like
CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.
This copyrighted material is provided by Natural Medicines Comprehensive Database Consumer Version. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
© Therapeutic Research Faculty 2020.